Investor Overview

ASH 2016 Poster: Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor
ASH 2016 Poster: The 9-Item Sickle Cell Disease Severity Measure (SCDSM): A Novel Measure of Daily SCD Symptom Severity Developed to Assess Benefit of GBT440, an Experimental HbS Polymerization Inhibitor
ASH 2016 Poster: Absorption, Metabolism, and Excretion of GBT440, a Novel Hemoglobin S (HbS) Polymerization Inhibitor for the Treatment of Sickle Cell Disease (SCD), in Healthy Male Subjects
Corporate Profile
Global Blood Therapeutics, Inc. (GBT), is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. We are developing our product candidate, GBT440, an oral, once-daily therapy that modulates hemoglobin affinity for oxygen. GBT440 potentially inhibits hemoglobin polymerization in sickle cell disease and potentially improves hypoxemia in idiopathic pulmonary fibrosis.
Stock Quote
GBT (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$24.40
Change (%)0.00 (0.00%)
Volume10,557
Data as of 02/22/17 4:00 p.m. ET
Refresh quote
Corporate Presentation
Download Documentation Corporate Presentation (February 2017)
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
02/22/17Global Blood Therapeutics Prices a $125.0 Million Upsized Common Stock Public Offering
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat grievous blood-based disorders with significant unmet need, today announced the pricing of its upsized underwritten public offering of 5,102,041 shares of its common stock at a price to the public of $24.50 per share. The gross proceeds to GBT from the offering, before deduc... 
Printer Friendly Version
02/21/17Global Blood Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat grievous blood-based disorders with significant unmet need, today announced an agreement to sell $75.00 million in shares of its common stock in a registered underwritten public offering. In addition, GBT has granted the underwriter a 30-day option to purchase up to $11.25 m... 
Printer Friendly Version
02/16/17Global Blood Therapeutics Announces Initiation of Phase 1 Trial to Evaluate the Physiologic Effects of GBT440 in Healthy Volunteers Under Hypoxemic Conditions
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced initiation of the Phase 1 Basecamp (GBT440-011) clinical trial, which is evaluating the physiologic effects of GBT440 in fit healthy volunteers under hypoxic conditions and exercise conditions that maximally stress the function of the heart and lungs. GBT440 is a hemoglobin modifier that left-shifts the oxygen-hemoglobin dissociation curve, which has the potentia... 
Printer Friendly Version
02/14/17Global Blood Therapeutics Announces Publication of Paper Describing Discovery of GBT440 in ACS Medicinal Chemistry Letters
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that a paper describing the discovery of GBT440 and its ability to bind to hemoglobin and prevent red blood cells from sickling was published online in ACS Medicinal Chemistry Letters, a peer-reviewed publication of the American Chemical Society. GBT440 is in Phase 3 development as a potentially disease-modifying therapy for sickle cell disease (SCD). The publicatio... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Global Blood Therapeutics Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.